AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$FLGT

Xie Jian sold $42K of FLGT

Xie Jian (President and COO) sold 2,127 shares of Fulgent Genetics, Inc. (FLGT) at $19.66 on 2026-09-02.

Original reporting
SEC EDGAR · Xie Jian
Published Sep 3, 2026, 11:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 3, 2026, 11:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$FLGT
Bearish
medium confidence
Mentioned
$FLGT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FLGTBearishLow
01

Why it matters

The disclosed sale is modest and unlikely to affect FLGT's price materially.

02

Market read

Routine insider sale with limited trading relevance.

03

What to watch

Insider may be diversifying or meeting personal liquidity needs; not necessarily related to company fundamentals.

Relevance 3/10Novelty 4/10Timing: post-market 2026-09-02

Background

Form 4 filing discloses insider transactions to the SEC; investors monitor these for signals.

Company-level read

Ticker impact

$FLGTBearishMedium confidence
Context

President and COO Xie Jian sold 2,127 shares for $41,809, reducing his stake to 359,924 shares.

Expected impact

Potential modest dip or flat price action; unlikely to move the stock materially.

Evidence & confidence

The sale amount is small relative to total holdings and market cap; traders may view it as routine.

Market effects

Sector

No broader sector impact; isolated insider transaction.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing, not a bearish signal.

Key entities

  • Company
    Fulgent Genetics, Inc.

    Biotech firm listed on NASDAQ under ticker FLGT.

  • Executive
    Xie Jian

    President and COO of Fulgent Genetics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

FLGT insider trading history →

Related articles

AUG 8
$FLGTMedAI 8/10

Fulgent Genetics (FLGT) Q2 2026 Earnings Call Transcript

Fulgent Genetics (FLGT) reported Q2 2026 revenue of $85.4M, up 4% year over year and 20% sequentially, driven by Bako Diagnostics and StrataDX integration. Non-GAAP gross margin was 31.3% and Adjusted EBITDA was a $17.1M loss. Full-year revenue guidance was cut to $330M-$340M due to lower collection rates from a billing system transition.

fool.com7 min
JUL 30
$FLGTMed

Fulgent Reports Second Quarter 2026 Financial Results

Fulgent Genetics, Inc. (FLGT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fulgent Reports Second Quarter 2026 Financial Results • Revenue of $85.4 million, growing 20.1% sequentially • GAAP gross profit of $25.7 million, or GAAP gross margin of 30.1%; Non-GAAP gross profit of $26.8 million, or Non-GAAP gross margin of 31.3% • GAAP loss of

SEC EDGAR 8-K6 min